Genexine Inc (095700) - Total Liabilities

Latest as of September 2025: ₩106.21 Billion KRW ≈ $71.98 Million USD

Based on the latest financial reports, Genexine Inc (095700) has total liabilities worth ₩106.21 Billion KRW (≈ $71.98 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore net asset growth rate of Genexine Inc to track the company's year-over-year net asset growth rate.

Genexine Inc - Total Liabilities Trend (2009–2024)

This chart illustrates how Genexine Inc's total liabilities have evolved over time, based on quarterly financial data. See 095700 free cash flow to operating cash ratio to measure how efficiently the company converts operating cash flow to free cash.

Genexine Inc Competitors by Total Liabilities

The table below lists competitors of Genexine Inc ranked by their total liabilities.

Company Country Total Liabilities
Namu Tech Co.Ltd
KQ:242040
Korea ₩64.24 Billion
Chasys
KO:033250
Korea ₩40.12 Billion
Thac Ba Hydropower JSC
VN:TBC
Vietnam ₫178.14 Billion
LUOYANG GLASS CO. H YC 1
F:LUG
Germany €10.33 Billion
Tamawood Ltd
AU:TWD
Australia AU$20.15 Million
Renergen Ltd.
JSE:REN
South Africa ZAC1.70 Billion
WeConnect
PA:ALWEC
France €246.84 Million
Mastech Holdings Inc
NYSE MKT:MHH
USA $24.61 Million

Liability Composition Analysis (2009–2024)

This chart breaks down Genexine Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Genexine Inc market cap and net worth.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric Value Description
Current Ratio 0.58 Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio N/A More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio N/A Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity 0.41 Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets 0.29 Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Genexine Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Genexine Inc (2009–2024)

The table below shows the annual total liabilities of Genexine Inc from 2009 to 2024.

Year Total Liabilities Change
2024-12-31 ₩83.36 Billion
≈ $56.49 Million
+4.62%
2023-12-31 ₩79.68 Billion
≈ $54.00 Million
-29.25%
2022-12-31 ₩112.63 Billion
≈ $76.33 Million
-5.45%
2021-12-31 ₩119.12 Billion
≈ $80.73 Million
+94.32%
2020-12-31 ₩61.30 Billion
≈ $41.54 Million
+0.06%
2019-12-31 ₩61.27 Billion
≈ $41.52 Million
+12.82%
2018-12-31 ₩54.30 Billion
≈ $36.80 Million
+102.44%
2017-12-31 ₩26.83 Billion
≈ $18.18 Million
-5.77%
2016-12-31 ₩28.47 Billion
≈ $19.29 Million
+74.28%
2015-12-31 ₩16.33 Billion
≈ $11.07 Million
-6.94%
2012-12-31 ₩17.55 Billion
≈ $11.89 Million
+15.89%
2011-12-31 ₩15.14 Billion
≈ $10.26 Million
+34.71%
2010-12-31 ₩11.24 Billion
≈ $7.62 Million
+162.52%
2009-12-31 ₩4.28 Billion
≈ $2.90 Million
--

About Genexine Inc

KQ:095700 Korea Biotechnology
Market Cap
$75.97 Million
₩112.11 Billion KRW
Market Cap Rank
#20194 Global
#1039 in Korea
Share Price
₩2465.00
Change (1 day)
+5.34%
52-Week Range
₩2195.00 - ₩7100.00
All Time High
₩131402.78
About

Genexine, Inc., together with its subsidiaries, operates as a biotechnology company that focuses on the development and commercialization of immunotherapies in South Korea and internationally. The company develops its products through its hybrid Fc platform, a proprietary technology designed to develop long-acting protein drugs; and the DNA vaccine platform that is used to elicit immune responses… Read more